Chelsea Therapeutics International Lead Plaintiff Deadline - June 4, 2012: Levi & Korsinsky Reminds Investors With Losses On Their Investment In Chelsea Therapeutics International Of Class Action And The Lead Plaintiff Deadline
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Western District of North Carolina on behalf of investors who purchased Chelsea Therapeutics International Ltd. (“Chelsea” or the “Company”) (Nasdaq: CHTP) stock between November 3, 2008 and March 28, 2012.
For more information, click here: http://zlk.9nl.com/CHTP . There is no cost or obligation to you.
The complaint alleges that Chelsea made a series of materially false and misleading statements regarding the safety and efficacy of the drug Northera and the likelihood of its approval by the U.S. Food and Drug Administration (“FDA”). On February 13, 2012, Chelsea disclosed that the FDA had raised questions regarding the size and duration of its clinical trials for Northera. Furthermore, the FDA indicated that three deaths were potentially related to the drug. As a result of the aforementioned, shares of Chelsea stock declined more than 37 percent. Then on March 28, 2012, the Company announced that their New Drug Application for Northera was rejected by the FDA. Upon this news, Chelsea shares fell more than 28 percent, to close at $2.62 per share on March 29, 2012.
If you suffered a loss in Chelsea you have until June 4, 2012 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (877) 363-5972, or visit http://zlk.9nl.com/CHTP.
Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
